Acrivon Therapeutics, Inc. (ACRV)
NASDAQ: ACRV · Real-Time Price · USD
1.520
+0.030 (2.01%)
At close: Jun 17, 2026, 4:00 PM EDT
1.500
-0.020 (-1.32%)
After-hours: Jun 17, 2026, 6:55 PM EDT

Acrivon Therapeutics Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
6576188111253-
Market Cap Growth
78.87%-59.43%69.67%-56.12%--
Enterprise Value
-30.26-39.612.18-12129.730
Last Close Price
1.522.416.024.9211.52-
PB Ratio
0.620.681.060.911.48-
P/TBV Ratio
0.610.831.150.900.28-
EV/EBITDA Ratio
-0.48-0.18--
EV/EBIT Ratio
-0.47-0.18--
EV/FCF Ratio
-0.61-0.27--
Debt / Equity Ratio
0.010.010.010.030.020.05
Net Debt / Equity Ratio
-1.00-1.03-0.99-1.01-0.723.95
Net Debt / EBITDA Ratio
1.181.401.991.853.805.82
Net Debt / FCF Ratio
1.441.772.572.803.806.61
Quick Ratio
8.847.5710.439.5819.6134.18
Current Ratio
8.987.6910.559.7520.2734.46
Return on Equity (ROE)
-69.39%-49.56%-48.27%-36.80%-23.16%-32.51%
Return on Assets (ROA)
-69.34%-51.56%-53.28%-42.01%-22.69%-29.76%
Return on Invested Capital (ROIC)
-815.06%-635.78%-700.53%-226.29%-115.19%-442.85%
Return on Capital Employed (ROCE)
-78.12%-57.33%-58.62%-44.78%-23.46%-30.75%
Buyback Yield / Dilution
-2.31%-13.96%-53.06%-435.63%-136.43%-21.70%
Total Shareholder Return
-2.31%-13.96%-53.06%-435.63%-136.43%-21.70%
SEC Filings: 10-K · 10-Q